NICE accelerates breakthrough framework for complex liver diseases
NICE drives innovation, reshaping MASH evaluations with transformative guidance.
Athithi
Novartis secures triumphant $12 billion takeover of Avidity
The billion-dollar acquisition advances Avidity’s RNA platform with momentum.
Biogen Secures Breakthrough Edge in Immunology with $1B Vanqua Buy
Biogen strengthens Immunology pipeline through $1B Vanqua acquisition deal.
Sanofi Secures Breakthrough FDA Review for Tzield
Sanofi’s Tzield gains FDA review for stage 3 T1D.
Pfizer Throws Down $7.3B Gauntlet in Obesity Race with Metsera Buyout
After internal setbacks, Pfizer is buying its way into the obesity drug market.
Bain Capital Acquires Mitsubishi Tanabe Pharma
Bain Capital, a leading global private investment firm with approximately $160 billion in assets under management, has announced its agreement to acquire Mitsubishi Tanabe Pharma Corporation (MTPC), a renowned Japanese pharmaceutical company with over 300 years of heritage. This transaction represents one of Bain Capital’s largest investments in the pharmaceutical sector and demonstrates its continued … Read more
Eli Lilly Shakes Up JPM25 with $2.5B Scorpion Buyout in Breast Cancer Battle
Eli Lilly kicked off the 2025 J.P. Morgan Healthcare Conference with a strategic acquisition of Scorpion Therapeutics, securing its PI3Kα pipeline for up to $2.5 billion in upfront payments and milestones. The deal marks a bold move in Lilly’s quest to compete with Novartis and Roche in the lucrative breast cancer market. A Renewed Push … Read more
GSK snaps up IDRx for up to $1.15B
Britan-based pharmaceutical giant GSK has agreed to acquire 100% of the outstanding equity interests (including all options and other incentive equity) in IDRx, a US-based, clinical-stage biopharmaceutical company focused on developing precision therapeutics for the treatment of gastrointestinal stromal tumors (GIST). The acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) being developed … Read more
Pfizer picks Triana Biomedicines to find Molecular Glues for Cancer
US pharmaceutical giant Pfizer announced a groundbreaking collaboration with Triana Biomedicines to develop Molecular Glue Degraders. The partnership aims to create multiple advanced therapies, including cancer. The collaboration is seen as a significant step forward in developing advanced medical treatments that can address challenging disease targets. Targeted protein degradation is a novel and fast-growing segment. … Read more
OncoC4 merged with AcroImmune
OncoC4, a biopharmaceutical firm in its final phases of developing advanced cancer therapies, is merging with AcroImmune, a developer of immunotherapies for malignant tumors and inflammatory diseases. The merger produces first- and best-in-class immunotherapies. Drs. Yang Liu and Pan Zheng co-founded OncoC4 and AcroImmune, and they share a common shareholder base. The combined firm was … Read more